JMP Securities analyst Michael GKing noted the FDA has issued a partial clinical hold for clinical trials evaluating Epizyme's tazemetostat, but he sees "a number of mitigating factors" to this negative news. Those include the fact that the Phase 2 FL and DLBCL trials are mostly enrolled and that the Phase 2 study in mesothelioma and epithelioid sarcoma are already fully enrolled. He sees it making sense that the FDA would issue a hold "out of an abundance of caution," given the pediatric indication, but he maintains an Outperform rating and $28 price target on Epizyme shares.